Granted Patent
B2
US 12,667,604 · App. 18/145,676 · Granted Jun 30, 2026
Combination therapy with controlled-release CNP agonists
Inventors:
Lars Holten-Andersen (Vanløse, DK); Vibeke Miller Breinholt (Frederiksberg, DK); Kennett Sprogøe (Holte, DK)
Assignee:
ASCENDIS PHARMA GROWTH DISORDERS A/S
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.
Claims (29)
1 . A method of stimulating bone growth in a patient, the method comprising administering to the patient an effective amount of a controlled-release C-type natriuretic peptide (CNP) agonist, wherein the patient is also administered human growth hormone resulting in a synergistic increase in bone growth from the controlled-release CNP agonist and the human growth hormone acting in combination;
wherein the controlled-release CNP agonist releases a CNP moiety, the amino acid sequence of which consists of SEQ ID NO:24, under physiological conditions with a release half-life of at least 6 hours, wherein the controlled-release CNP agonist is a compound of formula (IIf):
or a pharmaceutically acceptable salt thereof;
wherein
the unmarked dashed line indicates the attachment to a nitrogen provided by the side-chain of the lysine at position 26 of the CNP moiety by forming an amide bond; and
the dashed line marked with the asterisk indicates attachment to —Z having the structure
wherein
each —Z a is
wherein
each c1 is an integer independently ranging from 200 to 250.
2 . The method of claim 1 , wherein the human growth hormone is in its free form.
3 . The method of claim 1 , wherein the human growth hormone is in the form of a stable conjugate.
4 . The method of claim 1 , wherein the human growth hormone is a controlled-release compound.
5 . The method of claim 1 , wherein the controlled-release CNP agonist and the human growth hormone are administered separately.
6 . The method of claim 1 , wherein the controlled-release CNP agonist and the human growth hormone are formulated in one pharmaceutical composition for simultaneous administration.
7 . The method of claim 1 , wherein the disorder that benefits from stimulating bone growth is selected from the group consisting of achondroplasia, hypochondroplasia, short stature, dwarfism, osteochondrodysplasias, thanatophoric dysplasia, osteogenesis imperfecta, achondrogenesis, chondrodysplasia punctata , homozygous achondroplasia, camptomelic dysplasia, congenital lethal hypophosphatasia, perinatal lethal type of osteogenesis imperfecta, short-rib polydactyly syndromes, rhizomelic type of chondrodysplasia punctata , Jansen-type metaphyseal dysplasia, spondyloepiphyseal dysplasia congenita, atelosteogenesis, diastrophic dysplasia, congenital short femur, Langer-type mesomelic dysplasia, Nievergelt-type mesomelic dysplasia, Robinow syndrome, Reinhardt syndrome, acrodysostosis, peripheral dysostosis, Kniest dysplasia, fibrochondrogenesis, Roberts syndrome, acromesomelic dysplasia, micromelia, Morquio syndrome, metatrophic dysplasia, and spondyloepimetaphyseal dysplasia.
8 . The method of claim 1 , wherein the disorder that benefits from stimulating bone growth is achondroplasia.
9 . The method of claim 1 , further comprising administering the human growth hormone to the patient.
10 . The method of claim 9 , wherein the CNP agonist and the human growth hormone are administered separately to the patient.
11 . The method of claim 9 , wherein the human growth hormone is of formula (A1):
wherein n=200-250, or a pharmaceutically acceptable salt thereof.
12 . The method of claim 1 , wherein the controlled-release CNP agonist is a compound of formula (IIf′):
or a pharmaceutically acceptable salt thereof.
13 . The method of claim 12 , wherein
the dashed line marked with the asterisk in formula (IIf′), indicates attachment to —Z having the structure:
14 . The method of claim 1 , wherein each c1 is about 225.
15 . The method of claim 1 , wherein the amino acid sequence of the human growth hormone consists of SEQ ID NO:99.
16 . The method of claim 1 , wherein the controlled-release CNP agonist and human growth hormone are administered subcutaneously.
17 . The method of claim 1 , wherein the controlled-release CNP agonist and human growth hormone are administered via subcutaneous injection.
Priority Claims (1)
EP 16191456
· Sep 29, 2016
· regional
Continuity (2)
Division
16338185
References Cited (377)
US 5252714A
· Harris et al.
· 1993
[cited by applicant]
US 5340920A
· Matsuo et al.
· 1994
[cited by applicant]
US 5824784A
· Kinstler et al.
· 1998
[cited by applicant]
US 6743425B2
· Nakao
· 2004
[cited by applicant]
US 6833358B1
· Nakata et al.
· 2004
[cited by applicant]
US 7585837B2
· Shechter et al.
· 2009
[cited by applicant]
US 8198242B2
· Wendt et al.
· 2012
[cited by applicant]
US 8377884B2
· Wendt et al.
· 2013
[cited by applicant]
US 8551937B2
· Wakabayshi et al.
· 2013
[cited by applicant]
US 8618124B2
· Greenwald et al.
· 2013
[cited by applicant]
US 8703893B2
· Hernandez et al.
· 2014
[cited by applicant]
US 8754190B2
· Ashley et al.
· 2014
[cited by applicant]
US 8946405B2
· Ashley et al.
· 2015
[cited by applicant]
US 20030068313A1
· Nakao
· 2003
[cited by applicant]
US 20100316625A1
· Mankarious et al.
· 2010
[cited by applicant]
US 20120276190A1
· Fitzgerald et al.
· 2012
[cited by applicant]
US 20170080049A1
· Morozumi
· 2017
[cited by applicant]
US 20170368189A1
· Sprogoe et al.
· 2017
[cited by applicant]
US 20190255183A1
· Sprogøe et al.
· 2019
[cited by applicant]
US 20210069339A1
· Sprogøe et al.
· 2021
[cited by applicant]
US 20210077584A1
· Rau et al.
· 2021
[cited by applicant]
US 20210177952A1
· Rau et al.
· 2021
[cited by applicant]
US 20220211817A1
· Rau et al.
· 2022
[cited by applicant]
US 20220296682A1
· Rau et al.
· 2022
[cited by applicant]
US 20230116746A1
· Sprogøe et al.
· 2023
[cited by applicant]
CA 2763817A1
· 2004
[cited by applicant]
EP 0447971A2
· 1992
[cited by applicant]
EP 1333036A1
· 2003
[cited by applicant]
EP 0769554B1
· 2008
[cited by applicant]
EP 2275119A1
· 2011
[cited by applicant]
EP 1534334B1
· 2014
[cited by applicant]
EP 2853273A1
· 2015
[cited by applicant]
EP 3078387A1
· 2016
[cited by applicant]
EP 3135296A1
· 2017
[cited by applicant]
RU 2573911C2
· 2016
[cited by applicant]
WO WO20000072870A1
· 2000
[cited by applicant]
WO WO02089789A1
· 2002
[cited by applicant]
WO WO02098446A1
· 2002
[cited by applicant]
WO WO2004043396A2
· 2004
[cited by applicant]
WO WO2004047871A2
· 2004
[cited by applicant]
WO WO2005099768A2
· 2005
[cited by applicant]
WO WO2006005140A2
· 2006
[cited by applicant]
WO WO2006136586A2
· 2006
[cited by applicant]
WO WO2008031045A2
· 2008
[cited by applicant]
WO WO2008034122A2
· 2008
[cited by applicant]
WO WO2008136611A1
· 2008
[cited by applicant]
WO WO2008155134A1
· 2008
[cited by applicant]
WO WO2009009712A1
· 2009
[cited by applicant]
WO WO2009067639A2
· 2009
[cited by applicant]
WO WO2009086166A1
· 2009
[cited by applicant]
WO WO2009095479A2
· 2009
[cited by applicant]
WO WO2009143412A2
· 2009
[cited by applicant]
WO WO2009156481A1
· 2009
[cited by applicant]
WO WO2010033217A1
· 2010
[cited by applicant]
WO WO2010091122A1
· 2010
[cited by applicant]
WO WO2010135541A2
· 2010
[cited by applicant]
WO WO2011012722A1
· 2011
[cited by applicant]
WO WO2011075471A2
· 2011
[cited by applicant]
WO WO2011082368A2
· 2011
[cited by applicant]
WO WO2011089214A1
· 2011
[cited by applicant]
WO WO2011089215A1
· 2011
[cited by applicant]
WO WO2011089216A1
· 2011
[cited by applicant]
WO WO2011123813A2
· 2011
[cited by applicant]
WO WO2011144756A1
· 2011
[cited by applicant]
WO WO2013024047A1
· 2013
[cited by applicant]
WO WO2013024048A1
· 2013
[cited by applicant]
WO WO2013024049A1
· 2013
[cited by applicant]
WO WO2013024052A1
· 2013
[cited by applicant]
WO WO2013024053A1
· 2013
[cited by applicant]
WO WO2013036857A1
· 2013
[cited by applicant]
WO WO2013160340A1
· 2013
[cited by applicant]
WO WO2015083582A1
· 2015
[cited by applicant]
WO WO2015129812A1
· 2015
[cited by applicant]
WO WO2016020373A1
· 2016
[cited by applicant]
WO WO2016110577A1
· 2016
[cited by applicant]
WO WO2017020034A1
· 2017
[cited by applicant]
WO WO2017100400A2
· 2017
[cited by applicant]
WO WO2017118693A1
· 2017
[cited by applicant]
WO WO2017118698A1
· 2017
[cited by applicant]
WO WO2017118700A1
· 2017
[cited by applicant]
WO WO2017118703A1
· 2017
[cited by applicant]
WO WO2017118704A1
· 2017
[cited by applicant]
WO WO2017118707A1
· 2017
[cited by applicant]
WO WO2018060314A1
· 2018
[cited by applicant]
WO WO2020165081A1
· 2020
[cited by applicant]
Grigorian et al., Prot. Sci. 14:902-913 (2005) (Year: 2005).
[cited by examiner]
Bruno et al., “Basics and recent advances in peptide and protein drug delivery,” Ther Deliv. 4(11): 1443-1467, (Nov. 2013).
[cited by applicant]
Chen et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv Drug Deliv Rev., 65(10): 1357-1369, (Oct. 2013).
[cited by applicant]
Cohen, “Short-limb skeletal dysplasias and raniosynostosis: what do they have in common?” Pediatr Radiol, 27, 442-446, (1997).
[cited by applicant]
He et al., “ Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety,” Molecules, 24, 1855, (2019).
[cited by applicant]
Lu et al., “Linkers Having a Crucial Role in Antibody-Drug Conjugates,” Int. J. Mol. Sci, 17, 561, (2016).
[cited by applicant]
U.S. Appl. No. 17/526,481, Non-Final Office Action mailed Aug. 7, 2023.
[cited by applicant]
U.S. Appl. No. 17/538,971, Non-Final Office Action mailed May 25, 2023.
[cited by applicant]
U.S. Appl. No. 17/538,971, Notice of Allowance mailed Oct. 10, 2023.
[cited by applicant]
U.S. Appl. No. 17/752,664, Final Office Action mailed Aug. 28, 2023.
[cited by applicant]
U.S. Appl. No. 17/839,390, Non-Final Office Action mailed11-Jun. 2023.
[cited by applicant]
U.S. Appl. No. 17/842,436, Non-Final Office Action mailed Aug. 17, 2023.
[cited by applicant]
U.S. Appl. No. 17/842,436, Notice of Allowance mailed Jun. 26, 2023.
[cited by applicant]
U.S. Appl. No. 17/839,390, Requirement for Restriction/Election mailed Jul. 6, 2023.
[cited by applicant]
U.S. Appl. No. 17/848,180, Requirement for Restriction/Election mailed Sep. 13, 2023.
[cited by applicant]
“BioMarin Announces Decision to Start Phase 3 Program for PEG-PAL in 2Q 2013,” BioMarin, Press Release, 3 pages, (2012). [Author Unknown].
[cited by applicant]
“PEG Products,” JenKem Technology USA, 7 pages, (2015). [Retrieved from the Internet: <URL: http://www.jenkemusa.com/products>]. [Author Unknown].
[cited by applicant]
Ansel, et al., “Drug Dosage and Terminology,” Pharmaceutical Dosage Forms and Drug Delivery, Seventh Edition, pp. 48-53, (1999).
[cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 247:1306-1310, (1990). [Retrieved from the Internet May 18, 2011: <URL: http://www.sciencemag.org >].
[cited by applicant]
Delgado et al., “The Uses and Properties of PEG-Linked Proteins,” Critical Re-views in Therapeutic Drug Carrier Systems, , 9(3,4):249-304, (1992).
[cited by applicant]
Einav, et al., “The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors,” Journal of Infectious Diseases, 202(1):65-74, (2010).
[cited by applicant]
Farnum et al., “In vivo Delivery of Fluoresceinated Dextrans to the Murine Growth Plate: Imaging of Three Vascular Routes by Multiphoton Microscopy,” Anat Rec A Discov Mol Cell Evol Biol, 288(1):91-103, doi:10.1002/ar.a…
[cited by applicant]
Furuya et al., “Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, 183(3):964-969, (1992).
[cited by applicant]
Igaki et al., “Effects of Intravenously Administered C-type Natriuretic Peptide in Humans: Comparison with Atrial Natriuretic Peptide,” Hypertens Res, 21:7-13, (1998).
[cited by applicant]
Jiang, et al., “Effect of Sialylated O-Glycans in Pro-Brain Natriuretic Peptide Stability,” Clin Chem, 56(6): 959-966, (Jun. 2010).
[cited by applicant]
Klag, et al., “Advances in treatment of achondroplasia and osteoarthritis,” Human Molecular Genetics, vol. 25, No. R1, (2016).
[cited by applicant]
Lorget et al., “Evaluation of the Therapeutic Potential of a CNP Analog in a Fgfr3 Mouse Model Recapitulating Achondroplasia,” AJHG, 91(6):1108-1114, (2012).
[cited by applicant]
Martz et al., “sFGFR for achondroplasia,” SciBX, 6(40), 2 pages, doi:10.1038/scibx.2013.1120, (2013).
[cited by applicant]
Martz et al., “sFGFR for achondroplasia,” SciBX, Nature Publishing Group, 2 pages, (2013).
[cited by applicant]
Mehta, et al., “The Use of Somatropin (Recombinant Growth Hormone) in Children of Short Stature,” Pediatr Drugs, 4(1): 37-47, (2002).
[cited by applicant]
Merrifield, “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,” J. Am. Chem. Soc., 85(14):2149-2154, doi: 10.1021/ja00897a025, (1963).
[cited by applicant]
Molina Clinical Policy, Subject: Recombinant Human Growth Hormone: Pediatric Conditions Without GHD, Policy No. MCP-004-C, 24 pages, (2010).
[cited by applicant]
NOF America Corporation, Sunbright® CS, GS, AS, HS, TS and PS Series (NHS active esters/Carbonate), retreived from the internet at: www.nofamerica.com/store/index.php?dispatch=categories.view&category_id=7 on Mar. 19, 2…
[cited by applicant]
Oefner, et al., “Structure of Human Neutral Endopeptidase (Neprilysin) Complexed with Phosphoramindon,” J. Mol. Biol., 296, 341-349, (2000).
[cited by applicant]
Pejchalova, et al., “C-natriuretic peptide: An important regulator of cartilage,” Molecular Genetics and Metabolism, 92, 210-215, (2007).
[cited by applicant]
Potter et al., “Natriuretic peptide metabolism, clearance and degradation,” FEBS J, 278(11):1808-1817, doi: 10.1111/j.1742-4658.2011.08082.x, (2011).
[cited by applicant]
Ramaswami, et al., “Treatment of Achondroplasia with Growth hormones: Six Year of Experience,” Pediatric Research, 22 pages, (1999).
[cited by applicant]
Sakaguchi, et al., “Characterisation of C-type natriuretic peptide receptors in the gill of dogfish
[cited by applicant]
Samson et al., “C-type natriuretic peptide mediates the hypothalamic actions of the natriuretic peptides to inhibit luteinizing hormone secretion,” Endocrinology, 132(2):504-509, doi: 10.1210/END0.132.2.8425472, (1993).
[cited by applicant]
STNext search notes for U.S. Pat. No. 10,052,366, Accession No. 2013:644347, Dated Feb. 11, 2021.
[cited by applicant]
Takano, et al., “Molecular evolution of shark C-type natriuretic peptides,” Zoolog Sci, 11 (3):441-454, (1994).
[cited by applicant]
Tallarida, “Quantitative Methods for Assessing Drug Synergism,” Genes & Cancer, 2(11) pp. 1003-1008, (2011).
[cited by applicant]
Wang et al., “Effect of liposome-encapsulated C-type natriuretic peptide on vascular response,” Database Chemabs, 1 page, Accession No. 1999:790321, (1999).
[cited by applicant]
Wendt et al., “Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3-Related Dwarfism,” J Pharmacol Exp Ther, 353(1…
[cited by applicant]
Yamashita, et al., “Statin treatment rescues FGFR3 skeletal dysplasia phenotypes,” Nature, 513, 507-511, (2014).
[cited by applicant]
Yampolsky, et al., “The Exchangeability of Amino Acids in Proteins,” Genetics, 170: 1459-1472, (Aug. 2005).
[cited by applicant]
SG 11202107446Q Search Report mailed Nov. 17, 2022.
[cited by applicant]
SG 11202107446Q Written Opinion mailed Nov. 21, 2022.
[cited by applicant]
U.S. Appl. No. 15/538,641, Non-Final Office Action mailed Sep. 6, 2018.
[cited by applicant]
U.S. Appl. No. 15/538,641, Requirement for Restriction/Election mailed Jun. 14, 2018.
[cited by applicant]
U.S. Appl. No. 16/066,058, Non-Final Office Action mailed Feb. 23, 2021.
[cited by applicant]
U.S. Appl. No. 16/066,058, Non-Final Office Action mailed Dec. 31, 2019.
[cited by applicant]
U.S. Appl. No. 16/066,058, Notice of Allowance and Interview Summary mailed Mar. 11, 2022.
[cited by applicant]
U.S. Appl. No. 16/066,058, Requirement for Restriction/Election mailed Oct. 4, 2019.
[cited by applicant]
U.S. Appl. No. 16/066,980, Non-Final Office Action mailed Apr. 19, 2021.
[cited by applicant]
U.S. Appl. No. 16/066,980, Notice of Allowance mailed Dec. 13, 2021.
[cited by applicant]
U.S. Appl. No. 16/066,980, Requirement for Restriction/Election mailed Dec. 28, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,057, Corrected Notice of Allowance mailed Sep. 18, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,057, Final Office Action mailed Dec. 2, 2019.
[cited by applicant]
U.S. Appl. No. 16/067,057, Non-Final Office Action mailed Jun. 25, 2019.
[cited by applicant]
U.S. Appl. No. 16/067,057, Notice of Allowance mailed Apr. 9, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,057, Notice of Allowance mailed Jul. 29, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,070, Final Office Action mailed Aug. 28, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,070, Non-Final Office Action mailed Jan. 26, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,070, Non-Final Office Action mailed Dec. 30, 2019.
[cited by applicant]
U.S. Appl. No. 16/067,070, Notice of Allowance mailed Feb. 24, 2022.
[cited by applicant]
U.S. Appl. No. 16/067,070, Notice of Allowance mailed Oct. 18, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,070, Requirement for Restriction/Election mailed Aug. 21, 2019.
[cited by applicant]
U.S. Appl. No. 16/067,095, Final Office Action mailed Nov. 10, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,095, Non-Final Office Action mailed Mar. 20, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,095, Non-Final Office Action mailed Apr. 5, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,095, Non-Final Office Action mailed Nov. 19, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,095, Notice of Allowance and Interview Summary mailed Mar. 16, 2022.
[cited by applicant]
U.S. Appl. No. 16/067,095, Notice of Allowance mailed Jul. 28, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,095, Requirement for Restriction/Election mailed Oct. 10, 2019.
[cited by applicant]
U.S. Appl. No. 16/067,111, Final Office Action mailed Sep. 17, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,111, Non-Final Office Action mailed Feb. 5, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,111, Notice of Allowability mailed Dec. 6, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,111, Notice of Allowance mailed Sep. 1, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,111, Requirement for Restriction/Election mailed Aug. 30, 2019.
[cited by applicant]
U.S. Appl. No. 16/269,097, Non-Final Office Action mailed Feb. 14, 2020.
[cited by applicant]
U.S. Appl. No. 16/338,185, Final Office Action mailed Apr. 7, 2021.
[cited by applicant]
U.S. Appl. No. 16/338,185, Non-Final Office Action mailed Oct. 25, 2021.
[cited by applicant]
U.S. Appl. No. 16/338,185, Non-Final Office Action mailed Nov. 18, 2020.
[cited by applicant]
U.S. Appl. No. 16/338,185, Notice of Allowance mailed May 25, 2022.
[cited by applicant]
U.S. Appl. No. 16/338,185, Requirement for Restriction/Election mailed Jul. 6, 2020.
[cited by applicant]
U.S. Appl. No. 16/933,127, Non-Final Office Action mailed Dec. 27, 2021.
[cited by applicant]
U.S. Appl. No. 16/993,127, Requirement for Restriction/Election mailed Jul. 28, 2021.
[cited by applicant]
U.S. Appl. No. 17/005,272, Non-Final Office Action mailed Aug. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/184,561, Corrected Notice of Allowance mailed Sep. 23, 2021.
[cited by applicant]
U.S. Appl. No. 17/184,561, Non-Final Office Action mailed May 3, 2021.
[cited by applicant]
U.S. Appl. No. 17/184,561, Notice of Allowance mailed Aug. 18, 2021.
[cited by applicant]
U.S. Appl. No. 17/752,664, Non-Final Office Action mailed Mar. 23, 2023.
[cited by applicant]
U.S. Appl. No. 17/752,664, Requirement for Restriction/Election mailed Oct. 14, 2022.
[cited by applicant]
U.S. Appl. No. 17/842,436, Final Office Action mailed Mar. 3, 2023.
[cited by applicant]
U.S. Appl. No. 17/842,436, Non-Final Office Action mailed Nov. 21, 2022.
[cited by applicant]
U.S. Appl. No. 16/066,058, Final Office Action mailed Aug. 20, 2020.
[cited by applicant]
U.S. Appl. No. 16/067,070, Notice of Allowance mailed Jun. 3, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,111, Notice of Allowance mailed Feb. 5, 2021.
[cited by applicant]
U.S. Appl. No. 16/067,111, Notice of Allowance mailed May 12, 2021.
[cited by applicant]
U.S. Appl. No. 16/338,185, Notice of Allowance mailed Sep. 27, 2022.
[cited by applicant]
WIPO Application No. PCT/EP2016/050298, PCT International Preliminary Report on Patentability issued Jul. 11, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2016/050298, PCT International Search Report mailed Apr. 8, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2016/050298, PCT Written Opinion of the International Searching Authority mailed Apr. 8, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050201, PCT International Preliminary Report on Patentability issued Jul. 10, 2018.
[cited by applicant]
WIPO Application No. PCT/EP2017/050201, PCT International Search Report mailed Apr. 12, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050201, PCT Written Opinion of the International Searching Authority mailed Apr. 12, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/0502091, PCT International Preliminary Report on Patentability issued Jul. 10, 2018.
[cited by applicant]
WIPO Application No. PCT/EP2017/0502091, PCT Written Opinion of the International Searching Authority mailed Apr. 11, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050213, PCT International Preliminary Report on Patentability issued Jul. 10, 2018.
[cited by applicant]
WIPO Application No. PCT/EP2017/050213, PCT International Search Report mailed May 11, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050213, PCT Written Opinion of the International Searching Authority mailed May 11, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050217, PCT International Preliminary Report on Patentability issued Jul. 10, 2018.
[cited by applicant]
WIPO Application No. PCT/EP2017/050217, PCT International Search Report mailed Apr. 4, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050217, PCT Written Opinion of the International Searching Authority mailed Apr. 4, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050220, PCT International Preliminary Report on Patentability issued Jul. 10, 2018.
[cited by applicant]
WIPO Application No. PCT/EP2017/050220, PCT International Search Report mailed Apr. 10, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050220, PCT Written Opinion of the International Searching Authority mailed Apr. 10, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050224, PCT International Preliminary Report on Patentability issued Jul. 10, 2018.
[cited by applicant]
WIPO Application No. PCT/EP2017/050224, PCT International Search Report mailed Mar. 23, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/050224, PCT Written Opinion of the International Searching Authority mailed Mar. 23, 2017.
[cited by applicant]
WIPO Application No. PCT/EP2017/074596, PCT International Preliminary Report on Patentability issued Apr. 2, 2019.
[cited by applicant]
WIPO Application No. PCT/EP2020/053304, PCT International Search Report and Written Opinion of the International Searching Authority mailed Aug. 4, 2020.
[cited by applicant]
WIPO Application No. PCT/EP2017/0502091, PCT International Search Report mailed Apr. 11, 2017.
[cited by applicant]
U.S. Appl. No. 17/538,971, Notice of Allowance mailed May 9, 2024.
[cited by applicant]
EudraCT No. 2019-002754-22v1 Clinical trial results, Apr. 11, 2023.
[cited by applicant]
U.S. Appl. No. 17/538,971, Notice of Allowance mailed Jan. 18, 2024.
[cited by applicant]
U.S. Appl. No. 17/696,769, Requirement for Restriction/Election mailed Mar. 16, 2022.
[cited by applicant]
U.S. Appl. No. 17/752,664, Non-Final Office Action mailed Mar. 14, 2024.
[cited by applicant]
U.S. Appl. No. 17/842,436, Notice of Allowance mailed Apr. 5, 2024.
[cited by applicant]
U.S. Appl. No. 17/848, 180, Non-Final Office Action mailed Feb. 26, 2024.
[cited by applicant]
Abassi et al., “Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11,” Br. J. Pharmacol., 109:1024-1028, (1993).
[cited by applicant]
Abbey et al., “Lysophosphatidic Acid Inhibits C-Type Natriuretic Peptide Activation of Guanylyl Cyclase-B,” Endocrinology, 144(1):240-246, (2003).
[cited by applicant]
Barrett et al., “Oligopeptidases, and the Emergence of the Prolyl Oligopeptidase Family,” Biol. Chem. Hoppe-Seyler, 373:353-360, (Jul. 1992).
[cited by applicant]
Bartels et al., “Mutations in the Transmembrane Natriuretic Peptide Receptor NPR-B Impair Skeletal Growth and cause Acromesomelic Dysplasia, Type Maroteaux,” Am. J. Hum. Genet., 75:27-34, (2004).
[cited by applicant]
Bhatia et al., “Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development,” Current Neuropharmacology, 20:675-692, (2022).
[cited by applicant]
Biering-Sørensen, “Physical Measurements as Risk Indicators for Low-Back Trouble Over a One-Year Period,” Spine 9(2):106-119, (1984).
[cited by applicant]
Biomarin Pharmaceutical Inc., Annex I—Summary of Product Characteristics, VOXZOGO, 52 pgs., (Dec. 2021).
[cited by applicant]
Biomarin Pharmaceutical Inc., Highlights of Prescribing Information, VOXZOGO, 22 pgs., (Nov. 2021).
[cited by applicant]
Block et al., “The Role of Remote Monitoring in Evaluation Fatigue in Multiple Sclerosis: A Review,” Frontiers in Neurology, 13:878613, (Jun. 2022).
[cited by applicant]
Borsche et al., “Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects,” Journal of Parkinson's Disease, 11:45-60, (2021).
[cited by applicant]
Breinholt et al., “Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP,” Br J Clin Pharmacol., 88:4763-4772, (2022).
[cited by applicant]
Brusse et al., “Testing Functional Performance in People with Parkinson Disease,” Physical Therapy, 85(2):134-141, (Feb. 2005).
[cited by applicant]
Caliceti et al., “Improvement of the physicochemical and biopharmaceutical properties of insulin by poly(ethylene glycol) conjugation,” S.T.P. Pharma Sciences, 9(1):107-113, (1999).
[cited by applicant]
Carpenter et al., “Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice,” Rational Design of Stable Protein Formulations, 109-133, (2002).
[cited by applicant]
Chusho et al., “Dwarfism and early death in mice lacking C-type natriuretic peptide,” PNAS, 98(7):4016-4021, (Mar. 27, 2001).
[cited by applicant]
Clael et al., “Association of Strength and Physical Functions in People with Parkinson's Disease,” Neuroscience Journal, 2018(8507018):1-5, (Dec. 2018).
[cited by applicant]
Danielsen et al., “A neutral endopeptidase in the microvillar membrane of pig intestine,” Biochem J., 191:645-648, (1980).
[cited by applicant]
De Plater, et al., “A C-type natriuretic peptide from the venom of the platypus (
[cited by applicant]
Declaration of Daniel Wendt, 3 pgs., (Jan. 20, 2023).
[cited by applicant]
Declaration of Dr. Ulrich Hersel, 5 pgs., (Aug. 25, 2022).
[cited by applicant]
Domondon et al., “Regulation of mitochondria function by natriuretic peptides,” Am J Physiol Renal Physiol, 317:F1164-1168, (2019).
[cited by applicant]
Edman, “Method for determination of the amino acid sequence in peptides,” Acta Chemica Scandinavica, 4:282-293, (1950).
[cited by applicant]
Elmore, “Peptide Synthesis,” Techniques in Molecular Biology, 32-54, (1987).
[cited by applicant]
EP Application No. 16192229.9, Grounds for the Decision Annex dated Sep. 23, 2024.
[cited by applicant]
EP Application No. 16192229.9, Summons to Attend Oral Proceedings dated Jun. 18, 2024.
[cited by applicant]
EP Application No. 16192229.9, Transmittal of Decision dated Jun. 19, 2023.
[cited by applicant]
EP Application No. 3 175 863, Written Submissions dated Mar. 28, 2024, 25 pgs.
[cited by applicant]
EP Application No. 96 114 549.7, Applicant submission to EPO dated Nov. 14, 2006.
[cited by applicant]
Erdös et al., “Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones,” The FASEB Journal, 3:154-151, (Feb. 1989).
[cited by applicant]
Espiner et al., “C-type natriuretic peptide in Parkinson's disease: reduced secretion and response to deprenyl,” J. Neural Transm., 121:371-378, (2014).
[cited by applicant]
Felix, Site-Specific Poly(ethlene glycol)ylation Peptides, Poly(ethylene glycol), Chemistry and Biological Applications, American Chemical Society, Edited by Harris & Zalipsky, Chap. 16, 218-238, (1997).
[cited by applicant]
Genentech, Inc. XOLAIR® highlights of prescribing information, revised Sep. 2014.
[cited by applicant]
Goncalves et al., “In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia,” PLOS One, 15(12):e0244368, (2020).
[cited by applicant]
Graven-Nielsen et al., “Induction and Assessment of Muscle Pain, Referred Pain, and Muscular Hyperalgesia,” Current Pain and Headache Reports, 443-451, (2003).
[cited by applicant]
Greenwald et al., “A New Aliphatic Amino Prodrug System for the Delivery of Small Molecules and Proteins Utilizing Novel PEG Derivatives,” J. Med. Chem., 47:726-734, (2004).
[cited by applicant]
Greenwald et al., “Drug delivery systems based on trimethyl lock lactonization poly(ethylene glycol) prodrugs of amino-containing compounds,” J. Med. Chem., 43:475-487, (2000).
[cited by applicant]
Greenwald et al., “Drug delivery systems employing 1,4- or 1,6-elimination: Poly(ethylene glycol) prodrugs of amine-containing compounds,” J. Med. Chem., 42:3657-3667, (1999).
[cited by applicant]
Hinds et al., “Effects of PEG conjugation on insulin properties,” Advanced Drug Delivery Reviews, 54:505-530, (2002).
[cited by applicant]
Hinds et al., “Synthesis and Characterization of Poly(ethlene glycol)-Insulin Conjugates,” Bioconjugate Chem., 11:195-201, (2000).
[cited by applicant]
Hunt et al., “Bioactivity and Metabolism of C-Type Natriuretic Peptide in Normal Man,” Journal of Clinical Endocrinology and Metabolism, 78(5):1428-1435, (1994).
[cited by applicant]
Ishizaka et al., “Isolation and identification of C-type natriuretic peptide in human monocytic cell line, THP-1,” Biochemical and Biophysical Research Communications, 189(2):697-704, (Dec. 15, 1992).
[cited by applicant]
Itaba et al., “Presence of C-type natriuretic peptide (CNP) in guinea pig caecum: role and mechanisms of CNP in circular smooth muscle relaxation,” Neurogastroenterol Motil, 16:375-382, (2004).
[cited by applicant]
Iwata et al., “Metabolic Regulation of Brain Aβ by Neprilysin,” Science, 292:1550-1552, (May 25, 2001).
[cited by applicant]
Kenny et al., “Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11,” Biochem J., 291:83-88, (1993).
[cited by applicant]
Kitoh et al., “Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia,” PLOS One, 15(4):e0229639, (2020).
[cited by applicant]
Lebel et al., “Role of the neutral endopeptidase 24.11 in the conversion of big endothelins in guinea-pig lung parenchyma,” Brit Jour of Pharmacol., 117:184-188, (1996).
[cited by applicant]
Lisy et al., “Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin,” Physiology, F410-414, (Apr. 25, 2024).
[cited by applicant]
Mackler et al., “Oxidative Energy Deficiency. II. Human Achondroplasia,” Archives of Biochemistry and Biophysics, 159:885-888, (1973).
[cited by applicant]
Macours et al., “Structure, Evolutionary Conservation, and Functions of Angiotensin- and Endothelin-Converting Enzymes,” International Review of Cytology, 239:47-97, (2004).
[cited by applicant]
Mahesh et al., “Amide bond activation of biological molecules,” Molecules, 23:1-43, (2018).
[cited by applicant]
Marra et al., “An Overview of Mitochondrial Protein Defects in Neuromuscular Diseases,” Biomolecules, 11:1-39, (2021).
[cited by applicant]
Medeiros et al., “Processing and Metabolism of Peptide-YY: Pivotal Roles of Dipeptidyl peptidase-IV, Aminopeptidase-P and Endopeptidase-24.11*,” Endocrinology, 134(5):2088-2094, (1994).
[cited by applicant]
Minamino et al., “Characterization of immunoreactive human C-type natruiretic peptide in brain and heart,” Biochemical and Biophysical Research Communications, 149(1):535-542, (Aug. 30, 1991).
[cited by applicant]
Minamino et al., “Natriuretic Peptides in the Cardiovascular System,” Handbook of Biologically Active Peptides, Chap. 165, 1199-1207, (2006).
[cited by applicant]
Minamino et al., “N-Terminally Extended Form of C-Type Natriuretic Peptide (CNP-53) Identified in Porcine Brain,” 170(2):973-979, (Jul. 31, 1990).
[cited by applicant]
Miyashita et al., “Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity,” Diabetes, 58:2880-2892, (2009).
[cited by applicant]
Muraresku et al., “Mitochondrial Disease: Advances in clinical diagnosis, management, therapeutic development, and preventative strategies,” Curr Genet Med Rep., 6(2):62-72, (2018).
[cited by applicant]
Murayama et al., “Cloning and sequence analysis of a Bothrops jararaca cDNA encoding a precursor of seven bradykinin-potentiating peptides and a C-type natriuretic peptide,” PNAS, 94:1189-1193, (Feb. 1997).
[cited by applicant]
Nakagawa et al., “Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases,” Biology, 11:1017, (2022).
[cited by applicant]
Naqvi et al., “Muscle Strength Grading,” StatPearls—NCBI Bookshelf, 3 pgs., (2025).
[cited by applicant]
Nesher et al., “Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide,” Bioconjgate Chem., 19:342-348, (2008).
[cited by applicant]
Norman et al., “Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry,” Biochemical and Biophysical Research Communications, 175(1):22-3…
[cited by applicant]
Pasut et al., “Protein, peptide and non-peptide drug PEGylation for therapeutic application,” Expert Opin. Ther. Patents, 14(6):859-894, (2004).
[cited by applicant]
Peixoto De Barcelos et al., “Mitochondrial Dysfunction and Multiple Sclerosis,” Biology, 8(37):1-17, (2019).
[cited by applicant]
Perez-Ternero et al., “C-type natriuretic peptide is a pivotal regulator of metabolic homeostasis,” PNAS, 119(13):e2116470119, (2022).
[cited by applicant]
Perez-Ternero et al., “C-type natriuretic peptide preserves central neurological function by maintaining blood-brain barrier integrity,” Front. Mol. Neurosci., 15:991112, (2022).
[cited by applicant]
Pierart et al., “Effect of human endopeptidase 24.11 (“enkephalinase”) on IL-1-induced thymocyte proliferation activity,” Journal of Immunology, 140(11):3808-3811, (1988).
[cited by applicant]
Piccinin et al., “PGC-1s in the Spotlight with Parkinson's Disease,” International Journal of Molecular Sciences, 22(3847):1-20, (2021).
[cited by applicant]
Potter et al., “Natriuretic Peptides: Their Structures, Receptors, Physiologic Functions and Therapeutic Applications,” Handb Exp Pharmacol., 191:341-366, (2009).
[cited by applicant]
Potter et al., “Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions,” Endocrine Reviews, 27(1):47-72, (2006).
[cited by applicant]
Rauen, “The RASopathies,” Annu Rev Genomics Hum Genet., 14:355-369, (2013).
[cited by applicant]
Roberts et al., “Chemistry for peptide and protein PEGylation,” Advanced Drug Delivery Reviews, 64:116-127, (2012).
[cited by applicant]
Roche Data Sheet Herceptin® Trastuzumab 150 mg and 440 mg powder for concentrate for solution for infusion, 140625, (Jun. 2014).
[cited by applicant]
Rose et al., “Neuropeptide Y Fragments Derived by Neprilysin Processing Are Neuroprotective in a Transgenic Model of Alzheimer's Disease,” The Journal of Neuroscience, 29(4):1115-1125, (Jan. 28, 2009).
[cited by applicant]
Rosenkranz et al., “Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis,” dLife, 10:e61798, (2021).
[cited by applicant]
Saint-Laurent et al., “Obesity in achondroplasia patients: from evidence to medical monitoring,” Orphanet Journal of Rare Diseases, 14:253, (2019).
[cited by applicant]
Savarirayan et al., “Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies,” Ther Adv Musculoskel Dis, 14:1-13, (2022).
[cited by applicant]
Second Declaration of Dr. Ulrich Hersel, 4 pgs., (Mar. 27, 2024).
[cited by applicant]
Shirotani et al., “Neprilysin Degrades Both Amyloid β Peptides 1-40 and 1-42 Most Rapidly and Efficiently among Thiorphan- and Phosphor Amidon-sensitive Endopeptidases,” Journal of Biological Chemistry, 276(24)21895-219…
[cited by applicant]
Smith, “Peptide Sequencing by Edman Degradation,” Encyclopedia of Life Sciences, 1-3, (2001).
[cited by applicant]
Sponseller et al., “Patient Guide to Achondroplasia Kyphosis,” Johns Hopkins Orthopaedic Surgery, 3 pgs., (2003).
[cited by applicant]
Stawikowski et al., “Introduction to Peptide Synthesis,” Curr Protoc Protein Sci, 1-17, (Feb. 2002).
[cited by applicant]
Stewart et al., “Pediatric Disorders of Orthostatic Intolerance,” Pediatrics, 141:e20171673, (Jan. 2018).
[cited by applicant]
Stuart et al., “Physical activity monitoring to assess disability progression in multiple sclerosis,” Multiple Sclerosis Journal—Experimental, Translational and Clinical, 1-12, (2020).
[cited by applicant]
Sudoh et al., “C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain,” Biochemical and Biophysical Research Communications, 168(2):863-870, (Apr. 30, 1990).
[cited by applicant]
Suzuki et al., Isolation of high-molecular-weight C-type natriuretic peptide from the heart of a cartilaginous fish (European dogfish,
[cited by applicant]
Taraldsen et al., “Gait, physical function, and physical activity in three groups of home-dwelling older adults with diferent severity of cognitive impairment—a cross-sectional study,” BMC Geriatrics, 21:670, (2021).
[cited by applicant]
Tawaragi et al., “Gene and Precursor Structures of Human C-Type Natriuretic Peptide,” Biochemical and Biophysical Research Communications, 175(2):645-651, (Mar. 15, 1991).
[cited by applicant]
Tsubery et al., “Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification,” The Journal of Biological Chemistry, 279(37):38118-38124, (Sep. 10, 2004).
[cited by applicant]
U.S. Appl. No. 15/646,822, Protest under 37 CFR 1.291 dated Mar. 3, 2018.
[cited by applicant]
U.S. Appl. No. 17/428,604, Non-Final Office Action mailed Sep. 24, 2024.
[cited by applicant]
U.S. Appl. No. 17/428,604, Final Office Action mailed Dec. 2, 2024.
[cited by applicant]
U.S. Appl. No. 17/752,664, Final Office Action mailed Nov. 1, 2024.
[cited by applicant]
U.S. Appl. No. 17/839,390, Notice of Allowance mailed Aug. 21, 2024.
[cited by applicant]
U.S. Appl. No. 17/842,436, Corrected Notice of Allowance mailed Sep. 26, 2024.
[cited by applicant]
U.S. Appl. No. 17/842,436, Notice of Allowance mailed Jul. 23, 2024.
[cited by applicant]
U.S. Appl. No. 18/145,676, Non-Final Office Action mailed Oct. 17, 2024.
[cited by applicant]
U.S. Appl. No. 61/180,112, Certified copy of priority document mailed Jun. 3, 2010.
[cited by applicant]
U.S. Appl. No. 61/180,112, Notice of Recordation and Assignment dated Jan. 22, 2010.
[cited by applicant]
U.S. Appl. No. 61/254,563, Filing Receipt mailed Nov. 20, 2009.287.
[cited by applicant]
U.S. Appl. No. 61/254,563, Certified copy of priority document mailed Jun. 3, 2010.
[cited by applicant]
U.S. Appl. No. 61/254,563, Assignment and Notice of Recordation dated Jun. 9, 2010.
[cited by applicant]
Uchio et al., “Site-specific insulin conjugates with enhanced stability and extended action profile,” Advanced Drug Delivery Reviews, 35:289-306, (1999).
[cited by applicant]
Veronese, “Peptide and protein PEGylation: a review of problems and solutions,” Biomaterials, 22:405-417, (2001).
[cited by applicant]
Veronese, “The Impact of PEGylation on Biological Therapies” Biodrugs, 22:315-329, (2008).
[cited by applicant]
Vidovic et al., “Production and isotope labeling of antimicrobial peptides in
[cited by applicant]
Wang, “Lyophilization and development of solid protein pharmaceuticals,” International Journal of Pharmaceutics, 203, 1-60, (2000).
[cited by applicant]
Wiedlocha et al., “Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation,” Cells, 10:2231, (2021).
[cited by applicant]
Witte et al., “Reduced expression of PGC-1a partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex,” Acta Neuropathol, 125:231-243, (2013).
[cited by applicant]
Woodward et al., “Central and systematic C-type Natriuretic Peptide are both reduced in Parkinson's Disease,” Parkinsonism and Related Disorders, 1-5, (2017).
[cited by applicant]
Wu et al., “Furin-mediated Processing of Pro-C-type Natriuretic Peptide,” The Journal of Biological Chemistry, 278(28):25847-25852, (2003).
[cited by applicant]
Yasoda et al., “Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway,” Nature Medicine, 10(1):80-86, (Jan. 2004).
[cited by applicant]
Yasoda et al., “Systemic Administration of C-Type Natriuretic Peptide as a Novel Therapeutic Strategy for Skeletal Dysplasias,” Endocrinology, 150(7):3138-3144, (Jul. 2009).
[cited by applicant]
Youn et al., “High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation,” Journal of Controlled Release, 117:371-379, (2007).
[cited by applicant]
Youn et al., “Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypo calcemic efficacy,” Journal of Controlled Release, 1…
[cited by applicant]
Zappe et al., “PEGylation of cyanovirin-N, an entry inhibitor of HIV,” Advanced Drug Delivery, 60:79-87, (2000).
[cited by applicant]
Zhao et al., “Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1a) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis,” Molecular Neurodegeneration, 6:51, (…
[cited by applicant]
Zhao et al., “The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis,” Cells, 11:2049, (2022).
[cited by applicant]
Zheng et al., “PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease,” Sci Transl Med., 2(52):1-29, (Oct. 2010).
[cited by applicant]
Zhou et al., “Identification of the G protein-activating sequence of the single-transmembrane natriuretic peptide receptor C (NPR-C),” Am J. Physiol Cell Physiol, 284:C1255-1261, (2003).
[cited by applicant]
Kimura et al., “Neutral endopeptidase (ES 3.4.24.11) does not hydrolyze recombinant human interleukin-1β,” Immunology Letters, 21:109-114, (1991).
[cited by applicant]
EP Patent No. 31758963, Communication of the Board Appeal pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal mailed Aug. 7, 2025.
[cited by applicant]
EP Patent No. 31758963, Decision of the Board of Appeals mailed Dec. 1, 2025.
[cited by applicant]
EP Patent No. 31758963, Minutes of the Oral Proceedings mailed Oct. 22, 2025.
[cited by applicant]
EP Patent No. 31758963, Response to Statement of Grounds of Appeal mailed May 27, 2025.
[cited by applicant]
EP Patent No. 31758963, Submissions Responsive to Opponent 1's Reply to Patentee's Appeal mailed Jun. 27, 2025.
[cited by applicant]